| lucitanib (E 3810) / Clovis, Servier |
NCT04254471: This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients |
|
|
| Recruiting | 2/3 | 313 | RoW | AL3810, Lucitanib, E3810, E-3810, carboplatin + etoposide, Placebo | ShangHai HaiHe Pharmaceutical | Extensive-stage Small Cell Lung Cancer | 05/22 | 11/22 | | |
| Ongoing | 2 | 60 | China | lucitanib (E 3810) - Clovis, Servier | Shanghai Institute of Materia Medical;Chinese Academy of Sciences/ Chongqing Fuchuang Pharmaceutical Research Co., Ltd | Thymic carcinoma | | | | |
ChiCTR2000041490: A single-arm, open-label, phase 2 clinical trial of Tislelizumab combined with Lucitanib for secondary hemophagocytic lymphohistiocytosis. |
|
|
| Recruiting | 2 | 29 | China | Baizean (tislelizumab) - BeiGene, Novartis, lucitanib (E 3810) - Clovis, Servier | Institute of Hematology & Hospital of Blood DiseasesChinese Academy of Medical Sciences & Peking Union Medical College | Hemophagocytic lymphohistiocytosis;Oncoogy | | | | |
2018-004283-65: A clinical study evaluating nivolumab-containing treatments in patients with advanced non-small cell lung cancer after failing previous PD-[L]1 therapy and chemotherapy |
|
|
| Not yet recruiting | 1/2 | 550 | Europe | NIVOLUMAB - 10mL vial- COMMERCIAL, Ipilimumab, Cabozantinib, Lucitanib, Docetaxel, BMS-936558, BMS-734016, XL184, CO-3810, Concentrate for solution for infusion, Film-coated tablet, Tablet, Opdivo (100 mg/10 mL), Cyramza 10 mg/ml concentrate for solution for infusion, Docetaxel Ebewe 10 mg/ml concentrate for solution for infusion, Doce NC® 10 mg/ml concentrate for solution for infusion | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation | Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) Immunotherapy, Non-small cell lung cancer that has spread or has reoccurred after failure of chemotherapy and immunotherapy, Diseases [C] - Cancer [C04] | | | | |
2019-002980-81: A study to evaluate lucitanib in combination with nivolumab in patients with a solid tumor Eine Studie zur Beurteilung von Lucitanib in Kombination mit Nivolumab bei Patienten mit einem soliden Tumor |
|
|
| Not yet recruiting | 1/2 | 161 | Europe | Lucitanib 1 mg tablet (Formulation A), Lucitanib 2 mg tablet (Formulation A), Lucitanib 5 mg tablet (Formulation A), Nivolumab, Lucitanib 2 mg tablet (Formulation B), CO-3810, BMS-936558, Film-coated tablet, Concentrate for solution for infusion, Opdivo (100mg/10ml) | Clovis Oncology, Inc., CLOVIS ONCOLOGY, INC, Clovis Oncology, Inc. | Advanced gynecological solid tumor, Advanced gynecological solid tumor Fortgeschrittener gynäkologischer solider Tumor, Diseases [C] - Cancer [C04] | | | | |
ChiCTR2400087935: An open-lable phase Ib/II study, Lucitanib combined with Toripalimab in the treatment of advanced recurrent or metastatic solid tumors |
|
|
| Completed | 1/2 | 180 | | Oral Lucitanib+Intravenous Toripalimab(240mg/dose) | Sun Yat-sen University Cancer Center; Haihe Biopharma Co.,Ltd., The sponsor is responsible for the funding of the clinical trial | Advanced recurrent or metastatic solid tumors | | | | |
